Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/44706
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cristobal, Ignacio | - |
dc.contributor.author | Febrer, Laia | - |
dc.contributor.author | Crespo, Carlos | - |
dc.contributor.author | Arbat, Agnès | - |
dc.contributor.author | Hernandez, Francisco J. | - |
dc.contributor.author | Brosa, Max | - |
dc.date.accessioned | 2013-07-10T11:44:45Z | - |
dc.date.available | 2013-07-10T11:44:45Z | - |
dc.date.issued | 2011 | - |
dc.identifier.issn | 0301-2115 | - |
dc.identifier.uri | http://hdl.handle.net/2445/44706 | - |
dc.description.abstract | To compare the cost and effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) versus combined oral contraception (COC) and progestogens (PROG) in first-line treatment of dysfunctional uterine bleeding (DUB) in Spain. STUDY DESIGN: A cost-effectiveness and cost-utility analysis of LNG-IUS, COC and PROG was carried out using a Markov model based on clinical data from the literature and expert opinion. The population studied were women with a previous diagnosis of idiopathic heavy menstrual bleeding. The analysis was performed from the National Health System perspective, discounting both costs and future effects at 3%. In addition, a sensitivity analysis (univariate and probabilistic) was conducted. RESULTS: The results show that the greater efficacy of LNG-IUS translates into a gain of 1.92 and 3.89 symptom-free months (SFM) after six months of treatment versus COC and PROG, respectively (which represents an increase of 33% and 60% of symptom-free time). Regarding costs, LNG-IUS produces savings of 174.2-309.95 and 230.54-577.61 versus COC and PROG, respectively, after 6 months-5 years. Apart from cost savings and gains in SFM, quality-adjusted life months (QALM) are also favourable to LNG-IUS in all scenarios, with a range of gains between 1 and 2 QALM compared to COC and PROG. CONCLUSIONS: The results indicate that first-line use of the LNG-IUS is the dominant therapeutic option (less costly and more effective) in comparison with first-line use of COC or PROG for the treatment of DUB in Spain. LNG-IUS as first line is also the option that provides greatest health-related quality of life to patients. | - |
dc.format.extent | 30 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier B.V. | - |
dc.relation.isformatof | Versió postprint del document publicat a: http://dx.doi.org/10.1016/j.ejogrb.2010.08.019 | - |
dc.relation.ispartof | European Journal Of Obstetrics & Gynecology And Reproductive Biology, 2011, vol. 154, num. 1, p. 71-80 | - |
dc.relation.uri | http://dx.doi.org/10.1016/j.ejogrb.2010.08.019 | - |
dc.rights | (c) Elsevier B.V., 2011 | - |
dc.source | Articles publicats en revistes (Genètica, Microbiologia i Estadística) | - |
dc.subject.classification | Ginecologia | - |
dc.subject.classification | Anàlisi econòmica | - |
dc.subject.classification | Espanya | - |
dc.subject.other | Gynecology | - |
dc.subject.other | Economic analysis | - |
dc.subject.other | Spain | - |
dc.title | Economic evaluation of the levonorgestrel-releasing intrauterine system for the treatment of dysfunctional uterine bleeding in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/acceptedVersion | - |
dc.identifier.idgrec | 579141 | - |
dc.date.updated | 2013-07-10T11:44:45Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
Appears in Collections: | Articles publicats en revistes (Genètica, Microbiologia i Estadística) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
579141.pdf | 584.04 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.